Intellia Therapeutics Inc (NASDAQ: NTLA) kicked off on Monday, down -42.23% from the previous trading day, before settling in for the closing price of $25.6. Over the past 52 weeks, NTLA has traded in a range of $5.90-$28.25.
Annual sales at Healthcare sector company slipped by -20.04% over the past five years. While this was happening, its average annual earnings per share was recorded 21.06%. With a float of $101.56 million, this company’s outstanding shares have now reached $105.33 million.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Intellia Therapeutics Inc is 5.39%, while institutional ownership is 88.00%. The most recent insider transaction that took place on Oct 01 ’25, was worth 539. In this transaction EVP, Chief Scientific Officer of this company sold 31 shares at a rate of $17.38, taking the stock ownership to the 105,184 shares. Before that another transaction happened on Oct 01 ’25, when Company’s VP, Chief Accounting Officer sold 1,871 for $17.38, making the entire transaction worth $32,518. This insider now owns 55,266 shares in total.
Intellia Therapeutics Inc (NTLA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.34 earnings per share (EPS), higher than consensus estimate (set at -1.37) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.55% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Take a look at Intellia Therapeutics Inc’s (NTLA) current performance indicators. Last quarter, stock had a quick ratio of 5.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 30.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.69, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.82 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 13.93 million, a positive change from its year-to-date volume of 4.77 million. As of the previous 9 days, the stock’s Stochastic %D was 43.91%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 35.72%, which indicates a significant increase from 10.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.50 in the past 14 days, which was higher than the 1.06 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.89, while its 200-day Moving Average is $11.43. Nevertheless, the first resistance level for the watch stands at $16.63 in the near term. At $18.47, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.18. If the price goes on to break the first support level at $13.08, it is likely to go to the next support level at $11.37. The third support level lies at $9.53 if the price breaches the second support level.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
The company with the Market Capitalisation of 1.59 billion has total of 107,347K Shares Outstanding. Its annual sales at the moment are 57,880 K in contrast with the sum of -519,020 K annual income. Company’s last quarter sales were recorded 14,250 K and last quarter income was -101,260 K.
